{"id":7658,"date":"2018-06-10T01:00:00","date_gmt":"2018-07-27T09:26:34","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/2018\/07\/27\/%e6%97%a9%e7%9f%a5%e9%81%93-2024%e5%b9%b4%e5%85%a8%e7%90%8350%e5%a4%a7%e9%87%8d%e7%a3%85%e7%95%85%e9%94%80%e8%8d%af%e7%89%a9\/"},"modified":"2018-07-27T17:26:39","modified_gmt":"2018-07-27T09:26:39","slug":"%e6%97%a9%e7%9f%a5%e9%81%93-2024%e5%b9%b4%e5%85%a8%e7%90%8350%e5%a4%a7%e9%87%8d%e7%a3%85%e7%95%85%e9%94%80%e8%8d%af%e7%89%a9","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/7658\/","title":{"rendered":"\u65e9\u77e5\u9053| 2024\u5e74:\u5168\u740350\u5927\u91cd\u78c5\u7545\u9500\u836f\u7269"},"content":{"rendered":"
\n

\"\u65e9\u77e5\u9053|<\/p>\n

EvaluatePharma\u7b2c11\u7248\u76842018\u5e74\u5ea6\u4e16\u754c\u836f\u7269\u9884\u544a\uff0c\u57fa\u4e8e\u5168\u7403\u9886\u5148\u76847000\u5bb6\u5236\u836f\u548c\u751f\u7269\u79d1\u6280\u516c\u53f8\u7684\u8bc4\u4f30\u6c47\u96c6\u4e86\u8bb8\u591a\u6743\u5a01\u5206\u6790\uff0c\u7ed9\u6211\u4eec\u63d0\u4f9b\u4e86\u4e00\u4e2a\u9876\u7ea7\u7684\u6d1e\u5bdf\u529b\uff0c\u5185\u5bb9\u5305\u62ec2017\u5e74\u5230\u4e0d\u8fdc\u76842024\u5e74\uff0c\u4ece\u4e16\u754c\u91d1\u878d\u5e02\u573a\u5230\u533b\u836f\u884c\u4e1a\u7684\u53d1\u5c55\u73b0\u72b6\uff0c\u5f3a\u8c03\u4e86\u5904\u65b9\u836f\u9500\u552e\u3001\u4e13\u5229\u98ce\u9669\u3001\u7814\u53d1\u6295\u5165\u3001\u5168\u7403\u77e5\u540d\u54c1\u724c\u836f\u7269\u9500\u552e\u548c\u6cbb\u7597\u9886\u57df\u7684\u5e02\u573a\u8d8b\u52bf\uff0c\u8fd8\u5305\u62ec\u5bf9\u5168\u7403\u5236\u836f\u521b\u65b0\u7684\u5206\u6790\uff0c\u4ee5\u53ca\u5bf92024\u5e74\u7684\u533b\u836f\u7ba1\u7ebf\u4ef7\u503c\u521b\u9020\u3001\u589e\u957f\u6700\u5feb\u7684\u516c\u53f8\u548c\u6295\u8d44\u56de\u62a5\u7387\u6700\u9ad8\u7684\u516c\u53f8\u7684\u6d1e\u5bdf<\/span>\u3002\u5c3d\u7ba1\u5236\u836f\u884c\u4e1a\u53d1\u751f\u4e86\u5f88\u591a\u53d8\u5316\uff0c\u4f46\u81f3\u5c11\u6709\u4e00\u4e2a\u4e8b\u5b9e\u5728\u672a\u6765\u51e0\u5e74\u91cc\u5e94\u8be5\u4fdd\u6301\u4e0d\u53d8\u3002\u5728\u6211\u4eec\u8fdb\u51652018\u5e74\u4e0b\u534a\u5e74\u4e4b\u9645\uff0c\u5236\u836f\u884c\u4e1a\u5c40\u52bf\u4f3c\u4e4e\u66f4\u52a0\u7a33\u5b9a\u3002\u6839\u636eEvaluatepharma\u7684World Preview 2018\uff0c\u6211\u4eec\u9884\u8ba1\u8fd9\u4e2a\u884c\u4e1a\u7684\u9500\u552e\u989d\u5c06\u4ece\u91d1\u878d\u5371\u673a\u540e\u7684\u4f4e\u8ff7\u6c34\u5e73\u52a0\u901f\u589e\u957f\uff0c\u52302024\u5e74\uff0c\u5e74\u590d\u5408\u589e\u957f\u7387\u5c06\u8d85\u8fc76%\u3002\u5e02\u573a\u7684\u6269\u5f20\u5f88\u5927\u7a0b\u5ea6\u4e0a\u8981\u9760\u6301\u7eed\u7684\u672a\u6ee1\u8db3\u7684\u9700\u6c42\u6765\u9a71\u52a8\u3002<\/p>\n


<\/p>\n

Evaluatepharma@\u7684\u9884\u6d4b\u5171\u8bc6\u663e\u793a\uff0c\u827e\u4f2f\u7ef4\uff08AbbVie\uff09\u516c\u53f8\u7684\u91cd\u78c5\u70b8\u5f39\u7ea7\u836f\u7269\u4fee\u7f8e\u4e50\uff08Humira\uff09\u9884\u8ba1\u5c06\u57282024\u5e74\u7ee7\u7eed\u5f15\u9886\u5168\u7403\u836f\u54c1\u9500\u552e\u6392\u884c\u699c\uff0c\u53bb\u5e74\u5168\u7403\u9500\u552e\u989d\u8d85\u8fc72016\u5e74\u768425\u4ebf\u7f8e\u5143\uff0c\u521b\u4e0b\u4e86\u8be5\u516c\u53f8\u6709\u53f2\u4ee5\u6765\u7684\u6700\u9ad8\u7eaa\u5f55\u3002<\/span>Humira\u5728\u6162\u6027\u514d\u75ab\u5b66\u75be\u75c5\u7684\u81ea\u7136\u4f7f\u7528\u4e2d\u4e00\u822c\u4f5c\u4e3a\u9996\u9009\u7684\u4e00\u7ebfTNF\u6291\u5236\u5242\uff0c\u5176\u4ea4\u6613\u5df2\u7ecf\u8d76\u4e0a\u4e86\u5b89\u8fdb(Amgen)\u548c\u767e\u5065( Biogen)\uff0c\u9884\u671f\u5c06\u7f8e\u56fd\u751f\u7269\u7c7b\u4f3c\u836f\u5bf9Humira\u7684\u5e02\u573a\u51b2\u51fb\u63a8\u8fdf\u52302023\u5e74\u3002\u6839\u636eWorldPreview 2018\u62a5\u544a\uff0cHumira\u5728\u53bb\u5e74\u5b9e\u73b0189\u4ebf\u7f8e\u5143\u7684\u9500\u552e\u989d\u540e\uff0c\u57282024\u5e74\u7684\u9500\u552e\u989d\u5c06\u8fbe\u5230152.3\u4ebf\u7f8e\u5143\uff0c\u540c\u6bd4\u4e0b\u6ed13%\u3002\u6770\u5bcc\u745e(Jefferies)\u5206\u6790\u5e08\u9884\u8ba1\uff0c\u8be5\u836f\u7684\u9500\u552e\u989d\u660e\u5e74\u5c06\u8fbe\u5230204\u4ebf\u7f8e\u5143\u7684\u5cf0\u503c\u3002<\/p>\n


<\/p>\n

\u56e0\u6b64\uff0c\u867d\u7136\u5728\u672a\u6765\u76847\u5e74\u4e2d\uff0c\u5e74\u590d\u5408\u589e\u957f\u7387( compound annual growthrate\uff0cCAGR)\u4f1a\u67093%\u7684\u4e0b\u964d\uff0c\u4f46Humira\u5c06\u52bf\u5fc5\u4ecd\u7136\u8363\u767b2024\u5e74\u6700\u7545\u9500\u836f\u7269\u7684\u699c\u9996\u3002\u7d27\u968f\u5176\u540e\u7684\u662f\u9ed8\u514b\u7684Keytruda126.9\u4ebf\u7f8e\u5143\u548c\u65b0\u57fa\u7684Revlimid 119.3\u4ebf\u7f8e\u5143\uff0c\u767e\u65f6\u7f8e\u65bd\u8d35\u5b9d\u7684Opdivo\u4e3a112.5\u4ebf\u7f8e\u5143\uff0c\u767e\u65f6\u7f8e\u65bd\u8d35\u5b9d\u7684Eliquis\u4e3a105.4\u4ebf\u7f8e\u5143\u3002<\/span>\u9ed8\u6c99\u4e1c\u7684Keytruda\uff0c\u4e0d\u4ec5\u8d85\u8d8a\u4e86\u4e00\u76f4\u4ee5\u6765\u4f5c\u4e3a\u6700\u7545\u9500\u7684\u6297PD-1\u7684\u54c1\u79cd\u767e\u65f6\u7f8e\u65bd\u8d35\u5b9d\u7684\u7eb3\u6b66\u5355\u6297(Opdivo)\u7684\u9500\u91cf\uff0c\u5176CAGR\u6bd4\u7ade\u4e89\u5bf9\u624b\u9ad8\u51fa9%\uff0c\u800c\u4e14\u8d85\u8fc7\u4e86\u65b0\u57fa\u516c\u53f8\u7684\u91cd\u78c5\u70b8\u5f39\u8840\u6db2\u80bf\u7624\u836f\u7269\u6765\u90a3\u5ea6\u80fa(Revlinid)7.5\u4ebf\u7f8e\u5143\uff0c2017\u5e74\u6765\u90a3\u5ea6\u80fa\u7684\u5e74\u9500\u552e\u989d\u9ad8\u8fbe81.9\u4ebf\u7f8e\u5143\u3002<\/p>\n


<\/p>\n

Evaluatepharma\u672c\u5e74\u5ea6\u7684\u9884\u6d4b\u4e2d\u6709\u51e0\u4e2a\u54c1\u79cd\u4ecd\u7136\u8ba9\u4eba\u6ce8\u76ee\uff1a\u524d10\u540d\u4e2d\uff0c\u8fc7\u53bb\u6392\u540d\u7b2c17\u4f4d\u800c\u53bb\u5e74\u6210\u4ea4\u989d\u6700\u4f4e\u7684\u8d5b\u8bfa\u83f2\u7684Dupixent\u5c06\u57282024\u5e74\u8dc3\u5c45\u7b2c8\u4f4d\uff0c\u4e0e\u51762017\u5e74\u5c55\u671b2022\u5e74\u7684\u9884\u6d4b\u4e00\u81f4\uff0c\u51f8\u663e\u4e86\u8d5b\u8bfa\u83f2\u4e3b\u8981\u7684\u589e\u957f\u5f15\u64ce\u7684\u6f5c\u529b\uff0cDupixent\u6709\u671b\u57282018\u5e74\u665a\u4e9b\u65f6\u5019\u88ab\u6279\u51c6\u7528\u4e8e\u6cbb\u7597\u54ee\u5598\u3002\u8bc4\u4f30\u4e13\u5bb6\u9878\u6d4b\uff0c\u52302024\u5e74\u8be5\u836f\u6709\u671b\u4ece2017\u5e74\u76842.47\u4ebf\u7f8e\u5143\u6500\u5347\u81f380\u4ebf\u7f8e\u5143\uff0c\u5e73\u5747\u589e\u957f\u7387\u53ef\u4ee5\u8fbe\u523064%\u3002<\/span>\u53e6\u5916\uff0c\u524d50\u540d\u768417\u540d\u65b0\u4e0a\u699c\u8005\u4e2d\uff0c\u5409\u5229\u5fb7\u7684Biktarvy2017\u5e74\u51e0\u4e4e\u6ca1\u6709\u589e\u52a0\u4efb\u4f55\u9500\u552e\u5e02\u573a\uff0c\u4f46\u5206\u6790\u4e13\u5bb6\u9884\u6d4b\u5176\u5c06\u57282024\u5e74\u6709\u671b\u8fbe\u523060\u4ebf\u7f8e\u5143\u7684\u4efd\u989d\uff0c\u4e14\u662f\u8fd917\u4e2a\u65b0\u4e0a\u699c\u8005\u4e2d\u6700\u8000\u773c\u7684\u4e00\u4f4d\uff0c\u6392\u540d\u7b2c11\u4f4d\uff0c\u8d85\u8fc7\u4e86\u5176\u4ed6\u6240\u6709HIV\u7684\u836f\u7269\u3002<\/p>\n


<\/p>\n

2018\u5e74Evaluate’s\u76842024\u5e74\u5c55\u671b\u4e2d\u9884\u6d4b\u524d50\u540d\u4e2d\u4ec5\u4ec5\u6709\u4e09\u4e2a\u54c1\u79cd\u76ee\u524d\u6b63\u5904\u4e8e\u7814\u53d1\u9636\u6bb5\uff0c<\/span>\u5206\u522b\u662f\u56ca\u6027\u7ea4\u7ef4\u5316(CF)\u6cbb\u7597\u9886\u57df\u7684\u7edd\u5bf9\u9886\u5bfc\u8005\u798f\u6cf0\u5236\u836f(VertexPharmaceutical) VX-659+ Tezacaftor+ Ivacaftor\u7684\u4e09\u8054\u590d\u65b9\uff0c\u767e\u5065(Biogen)\u7684\u6cbb\u7597\u963f\u5c14\u8328\u6d77\u9ed8\u75c5\u7684Aducanumab \u4ee5\u53ca\u6cd5\u56fd\u751f\u7269\u5236\u836f\u516c\u53f8Genfit\u7684\u975e\u9152\u7cbe\u6027\u8102\u80aa\u809d\u836f\u7269Elafibranor\u3002\u57282024\u5e74\u798f\u6cf0\u5236\u836f\u4e09\u8054\u590d\u65b9\u7684\u6536\u5165\u9884\u8ba1\u4e3a34.85\u4ebf\u7f8e\u5143\uff0c\u6392\u5728\u7b2c36\u4f4d\u3002<\/span><\/p>\n

\u4e0b\u8868\u662f2018\u5e74\u5ea6\u5c55\u671b2024\u5e74\u5168\u7403\u524d50\u7684\u91cd\u78c5\u7545\u9500\u836f\u7269\uff1a<\/p>\n

\"\u65e9\u77e5\u9053|<\/p>\n

\"\u65e9\u77e5\u9053|<\/p>\n

\"\u65e9\u77e5\u9053|<\/p>\n

\"\u65e9\u77e5\u9053|<\/p>\n

\"\u65e9\u77e5\u9053|<\/p>\n

Note: Sales represent companyreported sales where available, otherwise based on an average of equity analystestimates.<\/span>
<\/p>\n


<\/p>\n

\u6839\u636eEvaluate pharma\u7684\u5e02\u573a\u8c03\u7814\u5206\u6790\u62a5\u544a\u6570\u636e\uff0c2017\u5e74\u5168\u7403\u524d50\u4e2a\u7545\u9500\u836f\u7269\u5e02\u573a\u603b\u503c\u7ea61377\u4ebf\u7f8e\u5143\uff0c\u9884\u8ba1\u5230 2018\u5e74\u81f32024\u5e74\u7684\u5e74\u590d\u5408\u6210\u957f\u7387\uff08compound annual growthrate\uff0cCAGR\uff09\u4e3a 10%\uff0c\u5230 2024\u5e74\u5e02\u573a\u603b\u503c\u7ea62670\u4ebf\u7f8e\u5143\u3002<\/span><\/p>\n


<\/p>\n

2024\u5e74\u5168\u740350\u5927\u7545\u9500\u836f\u7269\u7b80\u8ff0\u5982\u4e0b\uff1a<\/span><\/strong><\/p>\n


<\/span><\/strong><\/p>\n

1<\/span><\/strong><\/p>\n

 Humira<\/span><\/strong><\/p>\n

\"\u65e9\u77e5\u9053|<\/span><\/strong><\/p>\n

Humira<\/span><\/strong>\uff08Adalimumab\uff09<\/span><\/strong>\uff0c\u7531\u827e\u4f2f\u7ef4\uff08AbbVie\uff09\u7814\u53d1\u4e14\u9500\u552e\uff0c\u4e3b\u8981\u9002\u5e94\u75c7\u4e3a\u4e2d\u5ea6\u81f3\u91cd\u5ea6\u7c7b\u98ce\u6e7f\u6027\u5173\u8282\u708e\u3001\u5e72\u7663\u3001\u5e72\u7663\u6027\u5173\u8282\u708e\u3001<\/span>\u50f5<\/span>\u76f4\u6027\u810a<\/span>\u690e<\/span>\u708e\u3001\u514b\u9686\u6c0f\u75c7\uff08Crohn\u2019s disease\uff09\u3001\u6e83\u75a1\u6027\u7ed3\u80a0\u708e\u7b49\u81ea\u4e3b\u514d\u75ab\u75be\u75c5\u30022017\u5e74\u5168\u7403\u6536\u5165\u7ea6 189.2\u4ebf\u7f8e\u5143\uff0c\u8f832016 \u5e74\u589e\u957f14.6%\u3002Humira\u7684\u7f8e\u56fd\u4e13\u5229\u4e8e2016\u5e74\u5230\u671f\uff0c\u6b27\u6d32\u4e13\u5229\u4e5f\u5c06\u4e8e\u4eca\u5e74\u5230\u671f<\/span>\u3002<\/span>\u4ece1992\u5e74\u52302017\u5e74\uff0c\u4ec5Humira \u5c31\u7ed9 AbbVie \u5e26<\/span>\u6765\u4e86<\/span>757.2 \u4ebf\u7f8e\u5143<\/span>\u7684<\/span>\u6536\u5165\u3002<\/span><\/p>\n

2<\/strong><\/span><\/p>\n

Keytruda<\/strong><\/span><\/p>\n

\"\u65e9\u77e5\u9053|<\/strong><\/p>\n

Keytruda\uff0c\u662f\u80bf\u7624\u514d\u75ab\u6cbb\u7597\u5de8\u5934\u7f8e\u56fd\u9ed8\u6c99\u4e1c\uff08Merck&Co\uff09\u516c\u53f8\u7814\u53d1\u7684\u91cd\u78c5PD-1\u80bf\u7624\u514d\u75ab\u7597\u6cd5\u836f\u7269Keytruda\uff08pembrolizumab\uff0cMK-3475\uff09\u3002Keytruda\u88ab\u6279\u51c6\u7528\u4e8e\u5355\u836f\u4e00\u7ebf\u6cbb\u7597\u5c40\u90e8\u665a\u671f\u6216\u8f6c\u79fb\u6027\u9cde\u72b6\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC\uff09\u3001\u5c40\u90e8\u665a\u671f\u6216\u8f6c\u79fb\u6027\u9ed1\u8272\u7d20\u7624\u3001\u8180\u80f1\u764c\u3001\u665a\u671f\u809d\u7ec6\u80de\u764c\u3001\u80c3\u764c\u7b49\u53ca\u665a\u671f\u98df\u7ba1\u764c\u7684\u4e8c\u7ebf\u6cbb\u7597\u7b49\u30022017\u5e74\u5168\u7403\u6536\u5165\u7ea638.2\u4ebf\u7f8e\u5143\uff0c\u8f832016 \u5e74\u5927\u5e45\u589e\u957f172.7%\u3002\uff0c\u5168\u7403\u7545\u9500\u6392\u884c\u699c\u4e0a\u4e00\u8dc3\u8363\u5347\u5230\u4e86\u7b2c\u4e8c\u4f4d\u3002\u636eEvaluatepharm\u9884\u6d4b2024\u5e74\uff0c\u5176\u6536\u5165\u4f1a\u7a81\u7834126.9\u4ebf\u7f8e\u5143\uff0c\u589e\u52bf\u770b\u6da8\uff0c\u5e02\u573a\u7684\u6269\u5f20\u5f88\u5927\u7a0b\u5ea6\u4e0a\u53d6\u51b3\u4e8e\u6301\u7eed\u7684\u9700\u6c42\u9a71\u52a8\u3002<\/p>\n


<\/p>\n

3<\/strong><\/span><\/p>\n

Revlimid<\/strong><\/span><\/p>\n


<\/strong><\/p>\n

\"\u65e9\u77e5\u9053|<\/strong><\/p>\n

Revlimid\uff08Lenalidomide\uff09\uff0c\u7531\u7f8e\u56fd\u65b0\u57fa\uff08Celgene\uff09\u7814\u53d1\u9500\u552e\uff0c\u53bb\u5e747\u6708\u767e\u6d4e\u795e\u5dde(BeiGene)\u4e0e\u5168\u7403\u751f\u7269\u5236\u836f\u5de8\u5934\u65b0\u57fa\u533b\u836f(Celgene)\u8fbe\u6210\u6218\u7565\u5408\u4f5c\uff0c\u5168\u9762\u63a5\u624b\u65b0\u57fa\u5728\u4e2d\u56fd\u7684\u8fd0\u8425\u56e2\u961f\uff0c\u83b7\u5f97\u4e86\u65b0\u57fa\u5728\u4e2d\u56fd\u7684\u6297\u80bf\u7624\u4ea7\u54c1\u7684\u72ec\u5bb6\u6388\u6743\uff0c\u5305\u62ec\u6765\u90a3\u5ea6\u80fa\u3002\u5176\u4e3b\u8981\u9002\u5e94\u75c7\u4e3a\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff08multiplemyeloma\uff09\u30022017\u5e74\u5168\u7403\u6536\u5165\u7ea681.9 \u4ebf\u7f8e\u5143\uff0c\u8f832016 \u5e74\u589e\u957f17.5%\u3002Revlimid\u7684\u7f8e\u56fd\u4e13\u5229\u548c\u6b27\u76df\u4e13\u5229\u5206\u522b\u4e8e2027 \u5e74\u548c2022 \u5e74\u5230\u671f\uff0c\u4e13\u5229\u6743\u7684\u4fdd\u62a4\u4f7f\u5b83\u6210\u4e3a\u516c\u53f8\u6295\u8d44\u7ec4\u5408\u4e2d\u975e\u5e38\u91cd\u8981\u7684\u4ea7\u54c1\u3002<\/p>\n

4<\/strong><\/span><\/p>\n

Opdivo<\/strong><\/span><\/p>\n

\"\u65e9\u77e5\u9053|<\/strong><\/span><\/p>\n

Opdivo\uff08Nivolumab\uff09\uff0c\u7531\u767e\u65f6\u7f8e\u65bd\u8d35\u5b9d\uff08Bristol-Myers Squibb\uff09\u7814\u53d1\u9500\u552e\uff0c\u7eb3\u6b66\u5355\u6297\u662f\u4e00\u4e2a\u4eba\u7a0b\u5e8f\u6b7b\u4ea1\u53d7\u4f53-1(PD-1)\u9002\u7528\u4e3a\u963b\u65ad\u6297\u4f53\u6cbb\u7597\uff0c<\/span>\u7f8e\u56fdFDA\u6279\u51c6Opdivo\u7528\u4e8e\u94c2\u7c7b\u6cbb\u7597\u4e2d\u6216\u6cbb\u7597\u540e\u75be\u75c5\u8fdb\u5c55\u7684\u590d\u53d1\u6216\u6709\u4e0d\u80fd\u5207\u9664\u8d27\u8f6c\u79fb\u9ed1\u8272\u7d20\u7624\u53ca\u8f6c\u79fb\u6027\u5934\u9888\u9cde\u72b6\u7ec6\u80de\u764c\u60a3\u8005\u30022017\u5e74\u5168\u7403\u6536\u5165\u7ea6 57.3\u4ebf\u7f8e\u5143\uff0c\u8f83 2016 \u5e74\u589e\u957f20.9%\u3002<\/p>\n

5<\/strong><\/span><\/p>\n

Eliquis<\/strong><\/span><\/p>\n

\"\u65e9\u77e5\u9053|<\/strong><\/span><\/p>\n

Eliquis\uff08Apixaban\uff09\uff0c\u5546\u54c1\u540d\u827e\u4e50\u59a5\uff0c\u963f\u54cc\u6c99\u73ed\u7247\uff0c\u662f\u4e00\u79cd\u65b0\u578b\u3001\u53e3\u670d\u3001\u53ef\u9006\u3001\u9ad8\u5ea6\u9009\u62e9\u3001\u76f4\u63a5\u7684Xa\u51dd\u8840\u56e0\u5b50\u6291\u5236\u5242\u3002<\/span>\u7531\u767e\u65f6\u7f8e\u65bd\u8d35\u5b9dBristol-Myers Squibb\uff08BMS\uff09\u548c\u8f89\u745ePfizer \u5171\u540c\u7814\u53d1\u9500\u552e\u3002\u4e0e\u4f20\u7edf\u7684\u6297\u51dd\u836f\u7269\u76f8\u6bd4\uff0c\u827e\u4e50\u59a5\u7597\u6548\u66f4\u597d\uff0c\u5e76\u4e14\u4e0d\u589e\u52a0\u6216\u51cf\u5c11\u51fa\u8840\u7684\u53d1\u751f\u98ce\u9669\u3002\u76ee\u524d\uff0c\u7f8e\u56fdFDA\u548c\u6b27\u6d32EMA\u5df2\u6279\u51c6\u827e\u4e50\u59a5\u7528\u4e8e\u9884\u9632\u6210\u4eba\u5168\u9acb\u6216\u5168\u819d\u5173\u8282\u7f6e\u6362\u672f\u540e\u9759\u8109\u8840\u6813\u6813\u585e\u75c7\uff08\u4e5f\u79f0\u9759\u8109\u8840\u6813\u6216VTE\uff09\uff0c\u9884\u9632\u975e\u74e3\u819c\u6027\u623f\u98a4\u60a3\u8005\u5352\u4e2d\u548c\u4f53\u5faa\u73af\u6813\u585e\uff08\u4e5f\u79f0\u623f\u98a4\u5352\u4e2d\uff09\uff0c\u6cbb\u7597\u6df1\u9759\u8109\u8840\u6813\u6813\u585e\u75c7\uff08\u4e5f\u79f0\u6df1\u9759\u8109\u8840\u6813\u6216DVT\uff09\u548c\u80ba\u6813\u585e\uff08\u4e5f\u79f0PE\uff09\uff0c\u4ee5\u53ca\u9884\u9632DVT\u548cPE\u7684\u590d\u53d1\u30022017\u5e74\u5168\u7403\u6536\u5165\u7ea648.7\u4ebf\u7f8e\u5143\uff0c\u8f83 2016 \u5e74\u589e\u957f45.8%\uff0c\u9884\u8ba12024\u5e74\u53ef\u4ee5\u8fbe\u5230105.4\u4ebf\u7f8e\u5143\u3002\u5e02\u573a\u5bf9\u4e8eEliquis\u7684\u9700\u6c42\u8d8a\u6765\u8d8a\u5927\u4e3a\u5176\u6536\u5165\u5927\u5e45\u589e\u957f\u7684\u539f\u56e0\u3002Bristol-Myers Squibb CEO Giovanni Caforio\u8868\u793aEliquis\u4ecd\u6709\u5927\u5e45\u589e\u957f\u7684\u6f5c\u529b\u3002<\/p>\n

6<\/strong><\/span><\/p>\n

Imbruvica<\/strong><\/span><\/p>\n

\"\u65e9\u77e5\u9053|<\/strong><\/span><\/p>\n

Imbruvica\uff08Ibrutinib\uff09\uff0c\u4f9d\u9c81\u66ff\u5c3c\u662f\u7531Pharmacyclics\u548cJohnson & Johnson\u5171\u540c\u5f00\u53d1\u548c\u9500\u552e\u7684BTK\u6291\u5236\u5242\uff0c<\/span>2015\u5e74\u827e\u4f2f\u7ef4\uff08AbbVie\uff09\u4ee5210\u4ebf\u91cd\u91d1\u5c06\u5176\u6536\u8d2d\u3002\u8fd9\u4e2a\u65b0\u836f\u5982\u6b64\u5f15\u4eba\u77a9\u76ee\uff0c\u7adf\u8ba9\u7f8e\u56fdFDA\u4e00\u53e3\u6c14\u7ed9\u4e88\u4e86\u7a81\u7834\u6027\u836f\u7269\u3001\u4f18\u5148\u5ba1\u8bc4\u3001\u52a0\u901f\u6279\u51c6\u548c\u5b64\u513f\u836f\u56db\u91cd\u6279\u51c6\u7528\u4e8e\u5957\u7ec6\u80de\u6dcb\u5df4\u7624\u3002\u5957\u7ec6\u80de\u6dcb\u5df4\u7624\u662f\u4e00\u79cd\u7f55\u89c1\u975e\u970d\u5947\u91d1\u6dcb\u5df4\u7624\u3002\u9664\u4e86\u6cbb\u7597\u5957\u7ec6\u80de\u6dcb\u5df4\u7624\u5916\uff0c\u8fd8\u7528\u4e8e\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u3001\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\u30022017\u5e74\u5168\u7403\u6536\u5165\u7ea632\u4ebf\u7f8e\u5143\uff0c\u8f83 2016 \u5e74\u589e\u957f44.1%\uff0c\u9884\u8ba12024\u5e74\u53ef\u4ee5\u8fbe\u523095.6\u4ebf\u7f8e\u5143\u3002<\/h1>\n

7<\/strong><\/span><\/p>\n

Ibrance<\/strong><\/span><\/p>\n

\"\u65e9\u77e5\u9053|<\/strong><\/span><\/p>\n

Ibrance\uff08Palbociclib\uff09\uff0c\u662f\u7531\u8f89\u745e\uff08Pfizer\uff09\u5f00\u53d1\uff0c\u4e8e2015\u5e74FDA\u7ed9\u4e88\u7a81\u7834\u6027\u6cbb\u7597\u8ba4\u5b9a\u548c\u4f18\u5148\u5ba1\u8bc4\u52a0\u901f\u6279\u51c6\u7684\u9996\u4e2a\u7ec6\u80de\u5468\u671f\u86cb\u767d\u4f9d\u8d56\u6027\u6fc0\u91764\/6\uff08CDK4\/6\uff09\u6291\u5236\u5242\u3002<\/span>\u4e00\u79cd\u53e3\u670d\u7ec6\u80de\u5468\u671f\u7d20\u4f9d\u8d56\u6027\u6fc0\u9176\uff08CDKs\uff09\u53ef\u4ee5\u4e0e\u6765\u66f2\u5511\u8054\u5408\u5e94\u7528\u4f5c\u4e3a\u6cbb\u7597ER\u9633\u6027\/HER2\u9634\u6027\u7edd\u7ecf\u540e\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u7684\u4e00\u7ebf\u6cbb\u7597\u3002CDKs 4 \u548c6 \u662f\u7ec6\u80de\u5468\u671f\u7684\u5173\u952e\u8c03\u8282\u56e0\u7d20\uff0c\u5176\u80fd\u591f\u89e6\u53d1\u7ec6\u80de\u5468\u671f\u8fdb\u5c55\u30022017\u5e74\u5168\u7403\u6536\u5165\u7ea631.3\u4ebf\u7f8e\u5143\uff0c\u8f832016 \u5e74\u589e\u957f46.4%\uff0c\u9884\u8ba12024\u5e74\u53ef\u4ee5\u8fbe\u523082.8\u4ebf\u7f8e\u5143\u3002\u8fd9\u4e2a\u836f\u65e0\u8bba\u662f\u5bf9\u4e8e\u5168\u7403\u6570\u4ee5\u767e\u4e07\u8ba1\u7684\u60a3\u8005\u8fd8\u662fPfizer\u7684\u5b66\u672f\u529b\u91cf\u5bf9\u793e\u4f1a\u7684\u8d21\u732e\u90fd\u5177\u6709\u91cc\u7a0b\u7891\u5f0f\u7684\u610f\u4e49\u3002<\/p>\n

8<\/strong><\/span><\/p>\n

Dupixent<\/strong><\/span><\/p>\n

\"\u65e9\u77e5\u9053|<\/strong><\/span><\/p>\n

Dupixent\uff08dupilumab\uff09\uff0c\u662f\u7531\u8d5b\u8bfa\u83f2\uff08Sanofi\uff09\u548cRegeneron\u5171\u540c\u7814\u53d1\u548c\u9500\u552e\u7684\u6e7f\u75b9\u65b0\u836f\uff0c<\/span>\u7528\u4e8e\u6ce8\u5c04\u6cbb\u7597\u4e2d\u5ea6\u81f3\u91cd\u5ea6\u6e7f\u75b9(\u7279\u5e94\u884c\u76ae\u708e\uff0cAD)\u7684\u6210\u5e74\u4eba\uff0c\u9002\u7528\u4e8e\u7ecf\u5c40\u90e8\u6cbb\u7597\u4ecd\u4e0d\u80fd\u5145\u5206\u63a7\u5236\u7684\u6e7f\u75b9\uff0c\u6216\u90a3\u4e9b\u4e0d\u9002\u5408\u4f7f\u7528\u5c40\u90e8\u6cbb\u7597\u7684\u75c5\u4eba\u3002Dupixent\u662f\u9996\u4e2a\u83b7\u6279\u9488\u5bf9\u4e0a\u8ff0\u9002\u5e94\u75c7\u7684\u9776\u5411\u751f\u7269\u836f\u5242\u3002Dupixent\u662f\u4e00\u79cd\u4eba\u6e90\u5316\u7684\u5355\u514b\u9686\u6297\u4f53\uff0c\u5176\u8bbe\u8ba1\u4f5c\u7528\u4e8e\u7279\u5f02\u6027\u6291\u5236\u7684\u4e24\u79cd\u5173\u952e\u86cb\u767d\u767d\u7ec6\u80de\u4ecb\u7d20-4(IL-4)\u548c\u767d\u7ec6\u80de\u4ecb\u7d20-3(IL-13)\u7684\u8fc7\u5ea6\u4fe1\u53f7\u4f20\u5bfc\uff0c\u8fd9\u4e24\u79cd\u5173\u952e\u6027\u86cb\u767d\u5206\u5b50\u88ab\u8ba4\u4e3a\u662fAD\u4e2d\u6301\u7eed\u6027\u6f5c\u5728\u708e\u75c7\u7684\u4e3b\u8981\u9a71\u52a8\u56e0\u7d20\u3002\u4e2d\u5ea6\u81f3\u91cd\u5ea6\u7279\u5e94\u6027\u76ae\u708e\u60a3\u8005\u6709\u65f6\u8981\u5e94\u5bf9\u96be\u4ee5\u5fcd\u53d7\u7684\u75c5\u75db\uff0c\u8fd9\u6781\u5927\u7684\u5f71\u54cd\u4e86\u4ed6\u4eec\u7684\u751f\u6d3b\uff0c\u800c\u4e0e\u4e4b\u76f8\u5bf9\u7684\u7279\u5e94\u6027\u76ae\u708e\u53ef\u9009\u62e9\u7684\u6cbb\u7597\u65b9\u6848\u5f88\u5c11\uff0c\u8fd9\u4e5f\u5c31\u662f\u4e3a\u4ec0\u4e48\u4eca\u5e74\u5168\u7403\u7545\u9500\u6392\u884c\u699c\u4e0a\u7684Dupixent\u4ece\u53bb\u5e74\u768417\u540d\u4e00\u8dc3\u4e0a\u5347\u5230\u4e86\u7b2c8\u540d\u3002Evaluatepharma\u8bc4\u4f30\u5206\u6790\u5e08\u9878\u6d4b\uff0c\u52302024\u5e74\u8be5\u836f\u6709\u671b\u4ece2017\u5e74\u76842.47\u4ebf\u7f8e\u5143\u6500\u5347\u81f380\u4ebf\u7f8e\u5143\uff0c\u5e73\u5747\u589e\u957f\u7387\u53ef\u4ee5\u8fbe\u523064%\u3002<\/p>\n

9<\/strong><\/span><\/p>\n

Eylea<\/strong><\/span><\/p>\n

\"\u65e9\u77e5\u9053|<\/strong><\/span><\/p>\n

Eylea\uff08Aflibercept\uff09\uff0c\u7531\u7f8e\u56fdRegeneron \u836f\u5382\u7814\u53d1\uff0c\u5e76\u4e14\u548c\u5fb7\u56fd\u62dc\u8033\uff08Bayer\uff09\u548c\u6cd5\u56fd\u8d5b\u8bfa\u83f2\uff08Sanofi\uff09\u5171\u540c\u9500\u552e<\/span>\uff0c\u4e3b\u8981\u9002\u5e94\u75c7\u4e3a\u89c6\u7f51\u819c\u9ec4\u6591\u90e8\u75c5\u53d8\u30022017\u5e74\u5168\u7403\u8425\u6536\u7ea662.8\u4ebf\u7f8e\u5143\uff0c\u8f832016 \u5e74\u589e\u957f 13.4%\uff0c\u9884\u6d4b2024\u5e74\uff0c\u5168\u7403\u6536\u516568.27\u4ebf\u7f8e\u5143\u3002\u6b64\u836f\u57fa\u4e8e\u5e73\u7a33\u57fa\u6570\u7684\u60a3\u8005\u7fa4\u4f53\uff0c\u5728\u76ee\u524d\u6ca1\u6709\u5176\u4ed6\u7ade\u4e89\u529b\u7684\u5a01\u80c1\u4e0b\u4fdd\u6301\u4e86\u7a33\u5b9a\u7684\u8425\u6536\u3002<\/p>\n

10<\/span><\/strong><\/p>\n

Stelara<\/span><\/strong><\/p>\n

\"\u65e9\u77e5\u9053|<\/span><\/strong><\/p>\n

Stelara\uff08ustekinumab\uff09\uff0c\u4e4c\u53f8\u5974\u5355\u6297\u662f\u7531\u7f8e\u56fd\u5f3a\u751f\u7814\u53d1\u548c\u9500\u552e\uff0c\u4f5c\u4e3a\u94f6\u5c51\u75c5\u7684\u7ecf\u5178\u6807\u51c6\u7528\u836f\uff0c<\/span>\u867d\u7136\u5728\u4e34\u5e8a\u4e0a\u5c61\u5c61\u88abanti-IL17A\u7b49\u65b0\u661f\u5934\u5bf9\u5934\u6253\u8d25\uff0c\u4f46\u53d7\u76ca\u4e8e\u81ea\u8eab\u514d\u75ab\u75be\u75c5\u836f\u7269\u5e02\u573a\u7684\u6574\u4f53\u5feb\u901f\u6269\u5bb9\uff0cStelara\u57282017\u5e74\u4ecd\u7136\u5927\u6da824%\u5e76\u9996\u6b21\u7a81\u783440\u4ebf\u7f8e\u5143\u3002\u5f3a\u751f\u5728\u81ea\u8eab\u514d\u75ab\u75be\u75c5\u9886\u57df\u7684\u7ba1\u7ebf\u6bd4\u8f83\u539a\u5b9e\uff0c\u54c1\u89c4\u4e0d\u6b62Stelara\uff0c\u94f6\u5c51\u75c5\u5e02\u573a\u7ade\u4e89\u5347\u7ea7\u4e2d\u3002<\/p>\n


<\/p>\n

\u9650\u4e8e\u7bc7\u5e45\u548c\u8bfb\u8005\u5b9d\u8d35\u7684\u65f6\u95f4\uff0c\u7f16\u8005\u5c31\u4e0d\u5728\u6b64\u4e00\u4e00\u7f57\u5217\u5269\u4f5940\u4e2a\u7545\u9500\u836f\u7684\u7b80\u4ecb\u3002\u6709\u5174\u8da3\u7684\u53ef\u4ee5\u4ece\u5217\u8868\u6458\u51fa\u8fdb\u884c\u6df1\u5ea6\u8c03\u7814\u3002\u4ee5\u4e0a\u5185\u5bb9\u4ec5\u4ee3\u8868\u4e2a\u4eba\u89c2\u70b9\u548c\u836f\u4e8b\u5ba2\u89c2\u7efc\u8ff0\uff0c\u672c\u7740\u548c\u4f17\u4f4d\u836f\u53cb\u5206\u4eab\u4e92\u901a\u836f\u754c\u65b0\u95fb\u5927\u4e8b\u4ef6\uff0c\u82e5\u6709\u758f\u6f0f\u548c\u9519\u8bef\uff0c\u8bf7\u4e0d\u541d\u6307\u6b63\uff0c\u8c22\u8c22\uff01      <\/p>\n

       <\/span><\/p>\n

\u6392\u7248\uff1a\u6587\u7af9<\/span><\/strong><\/span><\/p>\n

\n
\n
\n
\u5e7f\u800c\u544a\u4e4b<\/section>\n<\/section>\n<\/section>\n
\n
\n

\u2299 <\/span>\u540c\u5199\u610f\u57f9\u8bad\uff1a<\/span><\/strong><\/p>\n

\u65b0\u836f\u4e2d\u7f8e\u53cc\u62a5\u4e4b\u6cd5\u89c4\u628a\u63a7\u4e0e\u7533\u62a5\u5b9e\u8df5<\/span><\/a><\/p>\n

\u6ce8\u5c04\u5242\u4e00\u81f4\u6027\u8bc4\u4ef7\u653f\u7b56\u6cd5\u89c4\u4e0e\u5173\u952e\u6280\u672f<\/a><\/span><\/p>\n

\u5c0f\u5206\u5b50\u521b\u65b0\u836f\u7269\u53d1\u73b0\u2014\u2014\u7406\u8bba\u3001\u5b9e\u8df5\u3001\u8fc7\u7a0b\u4e0e\u5c55\u671b<\/a><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

\"\u65e9\u77e5\u9053|<\/a><\/p>\n

\n


<\/p>\n

\u836f\u4e8b\u7eb5\u6a2a\u662f\u4e00\u4e2a\u5f00\u653e\uff0c\u7531\u81ea\u613f\u8005\u7ec4\u6210\u7684\u56e2\u4f53\uff0c\u73b0\u6709\u6210\u545840\u540d\uff0c\u5206\u522b\u4e3aVoyager88\uff08\u9b4f\u5229\u519b\uff09\uff0c\u96f7\u8bfa\u5c9b\uff0c\u4e09\u5206\u8bdd\uff0cHerman\uff0c\u6885\u5e0c\uff0c\u6587\u7af9\uff0cduke\uff0cyhqqqqq\uff0c\u5360\u5c0f\u5175\uff0c\u98ce\u4e00\u6837\u7684\u5c4e\u58f3\u90ce\uff0c\u9526\u5fc3\u7ee3\u53e3\uff0cflydp511\uff0c\u5de7\u5de7\uff0c\u4e91\u6c34\u9053\u4eba\uff0c\u9621\u4e0a\u964c\u964c\uff0c\u591a\u5df4\u80fa\uff0c\u745c\u513f\uff0cKailyn\uff0cSmall fish\uff0c\u5b50\u708e\uff0c\u514b\u683c\u83ab\uff0cVicky\uff0c\u4e07\u4e8b\u7686\u4e3a\u7a7a\uff0cPandada\uff0c\u83ab\u5306\u5306\uff0cSophia \uff0c\u4f9d\u7136\u7279\u96f7\u897f\uff0c\u5076\u9635\u96e8\uff0cAimee\uff0c\u4ed6\u5c71\u4e4b\u77f3\uff0c\u5510\u5c0f\u7396\uff0c\u96f6\u4e0b274\u2103\uff0cGloria\uff0c\u6ce2\u6ce2\uff0cBreathless\uff0cD.1\u53f7\uff0c\u80e1\u4e0d\u559c\uff0c Helen\uff0c\u843d\u843d\uff0cHERMIT\u3002\u6b22\u8fce\u6709\u5fd7\u4e4b\u58eb\u52a0\u5165\u6211\u4eec\u56e2\u961f\u3002\u6295\u7a3f\u3001\u5408\u4f5c\u3001\u52a0\u4e13\u4e1a\u7fa4\u8bf7\u52a0\u5fae\u4fe1442015666\uff0c\u836f\u4e8b\u7eb5\u6a2a\u4e8c\u5343\u4ebaQQ\u7fa422711855\u3002<\/span><\/p>\n


<\/p>\n

\n

\u59cb\u53d1\u4e8e\u5fae\u4fe1\u516c\u4f17\u53f7\uff1a \u836f\u4e8b\u7eb5\u6a2a <\/p>\n<\/blockquote>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

EvaluatePharma\u7b2c11\u7248\u76842018\u5e74\u5ea6\u4e16\u754c\u836f\u7269\u9884\u544a\uff0c\u57fa\u4e8e\u5168\u7403\u9886\u5148\u76847000\u5bb6\u5236\u836f\u548c\u751f\u7269\u79d1\u6280\u516c\u53f8\u7684\u8bc4 […]<\/p>\n","protected":false},"author":1,"featured_media":7659,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/7658"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=7658"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/7658\/revisions"}],"predecessor-version":[{"id":7677,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/7658\/revisions\/7677"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/7659"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=7658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=7658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=7658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}